Clinical Trial Update: The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma [NA]

View source ↗

Summary

Clinical trial update for a second-line combination of Iparomlimab and Tuvonralimab with albumin-bound paclitaxel in advanced gastric or gastroesophageal juncti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Qingxia Li | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | NA | Status: NOT_YET_RECRUITING